Afya Limited (AFYA)
| Market Cap | 1.29B -5.9% |
| Revenue (ttm) | 738.55M +7.9% |
| Net Income | 150.99M +12.7% |
| EPS | 1.67 +16.8% |
| Shares Out | 88.48M |
| PE Ratio | 8.74 |
| Forward PE | 7.49 |
| Dividend | $0.67 (4.57%) |
| Ex-Dividend Date | Mar 25, 2026 |
| Volume | 117,914 |
| Open | 14.38 |
| Previous Close | 14.31 |
| Day's Range | 14.27 - 14.73 |
| 52-Week Range | 13.00 - 16.50 |
| Beta | 0.38 |
| Analysts | Sell |
| Price Target | 16.88 (+15.7%) |
| Earnings Date | Aug 13, 2026 |
About AFYA
Afya Limited operates as a medical education group in Brazil. The company operates in three segments: Undergraduate, Continuing Education, and Medical Practice Solutions. The Undergraduate segment offers educational services through undergraduate courses related to medical school, health sciences, and other non-health undergraduate programs, including medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, biomedicine, business administration, accounting, law, civil and industrial engineering... [Read more]
Financial Performance
In 2025, Afya Limited's revenue was 3.70 billion, an increase of 11.89% compared to the previous year's 3.30 billion. Earnings were 752.46 million, an increase of 19.15%.
Financial numbers in BRL Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for AFYA stock is "Sell." The 12-month stock price target is $16.88, which is an increase of 15.70% from the latest price.
News
Afya comments on disclosure by Yduqs regarding potential business combination
Afya (AFYA) Limited announced that discussions with Yduqs Participacoes regarding a potential business combination involving the two companies are at an early stage, following the material fact disclo...
Afya Limited Comments on Recent Public Disclosure Made by Yduqs Participações S.A. Regarding a Potential Business Combination
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited, or “Afya” (Nasdaq: AFYA) announced today that discussions with Yduqs Participações S.A. (B3: YDUQ3) ("Yduqs") regarding a potential business comb...
Afya reports Q2 EPS R$2.22 vs. R$1.90 last year
Reports Q2 revenue R$972.1M vs. $919.4M last year. Q2 revenue excluding acquisitions increased 5.4% to R$969.3M. Afya (AFYA) management commented, “During the first half of 2026, Afya continued to exe...
Afya Limited Announces Second-Quarter and First-Half 2026 Financial Results
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, repor...
Afya Limited Earnings Call Transcript: Q2 2026
Revenue grew 7% and net income rose 7% year-over-year in the first half of 2026, with strong cash generation and disciplined capital allocation leading to over 100% of Free Cash Flow to Equity returned to shareholders. Competitive and regulatory factors impacted some segments, but guidance remains unchanged.
Afya Limited Earnings release: Q2 2026
Afya Limited released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Afya Limited Slides: Q2 2026
Afya Limited has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Afya Limited Slides: Investor presentation
Afya Limited has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Afya Announces Appointment of Marcelo Ken Suhara as the Chair Member of the Audit, Risks and Ethics Committee
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, annou...
Afya Limited Announces Results of Annual General Meeting Held on June 22, 2026
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited, or “Afya” (Nasdaq: AFYA) announced today that the resolution set out in its Notice of Annual General Meeting dated June 2, 2026 was duly passed a...
Afya price target lowered to $21 from $21.50 at JPMorgan
JPMorgan lowered the firm’s price target on Afya (AFYA) to $21 from $21.50 and keeps a Neutral rating on the shares. The firm updated its views on the Brazilian education…
Afya Limited Releases 2025 Integrated Report
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, annou...
Afya Limited (the "Company") Notice of Annual General Meeting of the Company
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Notice is hereby given that an Annual General Meeting of the Company (the "AGM") will be held at the offices of Afya Participações S.A., Rua Paraíba, No. 330, ...
Afya Limited Announces First-Quarter 2026 Financial Results
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, repor...
Afya Limited Earnings Call Transcript: Q1 2026
Revenue rose 8% year-over-year to BRL 1.013 billion, with net income up 2% and strong cash flow. Growth was driven by higher medical course tickets, expanding health programs, and investments in digital solutions, despite margin pressure from increased costs.
Afya Limited Earnings release: Q1 2026
Afya Limited released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Afya Limited Slides: Q1 2026
Afya Limited has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Afya Limited Slides: Investor presentation
Afya Limited has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Moody's Reaffirmed Afya's AAA.br Rating With a Stable Outlook
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, annou...
Afya price target lowered to $21.50 from $22 at JPMorgan
JPMorgan lowered the firm’s price target on Afya (AFYA) to $21.50 from $22 and keeps a Neutral rating on the shares. The firm updated the company’s estimates as part of…
Afya Limited Announces Fourth Quarter and Twelve Months 2025 Financial Results
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, repor...
Afya Limited Announces Dividend Distribution of R$307.4 Million
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, annou...
Afya Limited Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 12% revenue and 18% net income growth, robust cash flow, and a 19% EPS increase. 2026 guidance anticipates continued growth, with investments in technology and integration expected to impact margins.
Afya Limited Annual report: Q4 2025
Afya Limited has published its Q4 2025 annual report on March 12, 2026.
Afya Limited Earnings release: Q4 2025
Afya Limited released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.